Why the study?
Does dietary omega-3 fatty acid supplementation prolong platelet survival in hyperlipidemic patients with established atherothrombotic disorders?
Does dietary omega-3 fatty acid supplementation prolong platelet survival in hyperlipidemic patients with established atherothrombotic disorders?
Answers are grounded in this paper and cite their sources.
Dietary omega-3 fatty acid supplementation prolongs platelet survival, indicating suppressed in vivo platelet activity, in hyperlipidemic patients with atherosclerosis.
Enhanced dietary omega-3 fatty acid consumption is thought to be associated with a reduced incidence of atherothrombotic disorders. This effect may be mediated in part through suppression of in vivo platelet activity by omega-3 fatty acids. We observed that platelet survival, a sensitive indicator of in vivo platelet activity was prolonged from 6.4 +/- 1.5 days to 7.7 +/- 1.4 days by moderate amounts of dietary omega-3 fatty acid supplementation for 6 weeks in a group of hyperlipidemic patients with preexisting, established atherothrombotic disorders. This effect on platelet survival was associated with a decrease in platelet arachidonic acid levels from 26.7 +/- 3.5% to 20.9% +/- 2.5% and a rise in platelet eicosapentaenoic and docosahexaenoic acid measurements from essentially undetectable to 2.8% +/- 1.6% and 1.9% +/- 1.0%. Plasma total cholesterol, low-density lipoprotein cholesterol, and serum apolipoprotein B levels rose significantly during the omega-3 fatty acid supplementation period. Platelet aggregation did not change. This study demonstrates that a modest amount of dietary omega-3 fatty acid supplementation can significantly effect in vivo platelet activity in a population at high risk for recurrent atherothrombotic disorders.
No takes yet. Share an insight, caveat, or question.
Peter H. Levine (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: